Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 34 clinical trials
Featured trial
Do You Have Osteoporosis?

Do You Have Osteoporosis?

  • 1136 views
  • 25 Mar, 2021
  • 1 location
None
A Study to Evaluate the Reactogenicity Safety Immunogenicity and Efficacy of GlaxoSmithKline (GSK) Biologicals' HBV (Hepatitis B Virus) Viral Vector Vaccines and Adjuvanted Proteins Vaccine (GSK3528869A) in Adult Patients With Chronic Hepatitis B Infection.

A First-Time-In-Human study on GSK's therapeutic vaccines to evaluate the reactogenicity, safety, immunogenicity and efficacy on reduction of serum HBV surface antigen in HBV suppressed subjects

hepatitis b e antigen
fibroscan
vaccine therapy
hepatitis b core antibody
bilateral oophorectomy
  • 18 views
  • 05 Jun, 2021
  • 34 locations
None
A Study of JNJ-73763989 Pegylated Interferon Alpha-2a and Nucleos(t)Ide Analogs in Participants With Chronic Hepatitis B Virus Infection

The purpose of this study is to evaluate the efficacy in terms of hepatitis B surface antigen (HBsAg) changes from baseline for the treatment regimens of 24 weeks of JNJ-73763989 + 24 weeks of

  • 0 views
  • 02 Dec, 2021
  • 23 locations
None
A Study of JNJ-73763989 JNJ-56136379 Nucleos(t)Ide Analogs and Pegylated Interferon Alpha-2a in Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection

The purpose of this study is to evaluate the efficacy in terms of hepatitis B surface antigen (HBsAg) levels of the study intervention (that is, JNJ-73763989 + JNJ-56136379 + nucleos[t]ide

  • 0 views
  • 28 Nov, 2021
  • 14 locations
None
The Clinical Cure Project of Chronic Hepatitis B in China

nucleot(s)ide analogues(NAs) for some period can achieve higher hepatitis B surface antigen(HBsAg) clearance rate(which is called clinical cure or functional cure) by using pegylated interferon. Patients

cancer
hepatitis b e antigen
fibrosis
cirrhosis
interferon
  • 8 views
  • 24 Jan, 2021
  • 1 location
None
A Study of JNJ 73763989+JNJ 56136379+Nucleos(t)Ide Analog (NA) Regimen Compared to NA Alone in e Antigen Negative Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection

The purpose of this study is to evaluate the efficacy of 48-week study intervention with JNJ-73763989+JNJ-56136379+nucleos(t)ide analog (NA) regimen compared to NA alone assessed by HBsAg levels. This study is part of HepB Wings Platform Trial (PLATFORMPAHPB2001).

  • 6 views
  • 01 Mar, 2020
  • 32 locations
None
A Study of JNJ-73763989 Pegylated Interferon Alpha-2a Nucleos(t)Ide Analog (NA) With or Without JNJ-56136379 in Treatment-naive Participants With Hepatitis B e Antigen (HBeAg) Positive Chronic Hepatitis B Virus (HBV) Infection

The purpose of this study is to evaluate the efficacy of a treatment regimen of JNJ-73763989 + pegylated interferon alpha-2a (PegIFN-alpha-2a) + nucleos(t)ide analog (NA).

  • 0 views
  • 29 Nov, 2021
  • 59 locations
None
HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB)

A study to evaluate the antiviral effects, immunogenicity, and safety of HepTcell in treatment-naive patients with inactive Chronic Hepatitis B (CHB) and low Hepatitis B surface antigen (HBsAg

  • 0 views
  • 27 Jan, 2021
  • 1 location
None
Durvalumab for Advanced Hepatocellular Carcinoma in Patients With Active Chronic Hepatitis B Virus Infection

PD1 blockade has been approved as salvage therapy for advanced hepatocellular carcinoma (HCC). Although there is not solid evidence that PD1 blockade would induce hepatitis B virus (HBV) reactivation, previous clinical trials of PD1 blockade required enrolled patients to receive anti-HBV medications and control the viral load to be under …

  • 0 views
  • 24 Nov, 2021
  • 1 location
None
Combination Treatment of NAs and Peg IFN -2b for Hepatitis B Related Compensatory Cirrhosis Patients

The study aims to demonstrate that whether treatment of nucleoside acidanalogues (NAs) plus pegylated interferon (Peg IFN) -2b for those NAs treated, low level of HBsAg, hepatitis B related compensatory cirrhosis patients will result in higher HBsAg clearance rate and reduce the risk of liver cancer. The investigators plan to …

  • 0 views
  • 23 Jan, 2021
  • 1 location